Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 17 studies | 35% ± 20% | |
lung | 13 studies | 24% ± 7% | |
peripheral blood | 13 studies | 24% ± 10% | |
eye | 7 studies | 29% ± 14% | |
bone marrow | 4 studies | 19% ± 3% | |
kidney | 4 studies | 21% ± 3% | |
liver | 4 studies | 34% ± 12% | |
intestine | 4 studies | 22% ± 8% | |
adipose | 4 studies | 30% ± 7% | |
pancreas | 3 studies | 37% ± 18% | |
heart | 3 studies | 25% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2249.53 | 1445 / 1445 | 100% | 16.62 | 183 / 183 |
lung | 100% | 2038.45 | 578 / 578 | 99% | 10.61 | 1145 / 1155 |
ovary | 100% | 2403.99 | 180 / 180 | 99% | 8.06 | 424 / 430 |
stomach | 100% | 1637.12 | 359 / 359 | 98% | 10.50 | 281 / 286 |
breast | 100% | 2309.24 | 459 / 459 | 98% | 14.09 | 1098 / 1118 |
brain | 100% | 1941.00 | 2635 / 2642 | 98% | 12.76 | 694 / 705 |
intestine | 100% | 2197.96 | 966 / 966 | 98% | 9.56 | 515 / 527 |
bladder | 100% | 2247.38 | 21 / 21 | 96% | 8.83 | 485 / 504 |
prostate | 100% | 2094.64 | 245 / 245 | 96% | 9.46 | 481 / 502 |
pancreas | 100% | 1066.77 | 327 / 328 | 96% | 9.11 | 171 / 178 |
thymus | 100% | 2306.75 | 653 / 653 | 95% | 10.11 | 577 / 605 |
skin | 100% | 2479.44 | 1809 / 1809 | 95% | 11.57 | 449 / 472 |
kidney | 100% | 1494.73 | 89 / 89 | 94% | 7.69 | 844 / 901 |
uterus | 100% | 2531.44 | 170 / 170 | 93% | 9.42 | 429 / 459 |
adrenal gland | 100% | 1935.98 | 258 / 258 | 90% | 8.11 | 208 / 230 |
liver | 100% | 786.58 | 225 / 226 | 71% | 3.39 | 289 / 406 |
adipose | 100% | 2220.20 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2166.69 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2305.07 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2097.22 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.35 | 1 / 1 |
heart | 97% | 1413.68 | 836 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 8.57 | 41 / 45 |
lymph node | 0% | 0 | 0 / 0 | 86% | 7.63 | 25 / 29 |
peripheral blood | 71% | 1083.96 | 664 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 71% | 5.18 | 57 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051168 | Biological process | nuclear export |
GO_1990116 | Biological process | ribosome-associated ubiquitin-dependent protein catabolic process |
GO_0072344 | Biological process | rescue of stalled ribosome |
GO_0140708 | Biological process | CAT tailing |
GO_0065003 | Biological process | protein-containing complex assembly |
GO_1990112 | Cellular component | RQC complex |
GO_0022626 | Cellular component | cytosolic ribosome |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0043023 | Molecular function | ribosomal large subunit binding |
GO_1904678 | Molecular function | alpha-aminoacyl-tRNA binding |
GO_0000049 | Molecular function | tRNA binding |
Gene name | NEMF |
Protein name | Ribosome quality control complex subunit NEMF (Antigen NY-CO-1) (Nuclear export mediator factor) (Serologically defined colon cancer antigen 1) Nuclear export mediator factor Alternative protein NEMF |
Synonyms | SDCCAG1 |
Description | FUNCTION: Key component of the ribosome quality control complex (RQC), a ribosome-associated complex that mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes as well as their ubiquitin-mediated proteasomal degradation . Thereby, frees 60S subunit ribosomes from the stalled translation complex and prevents the accumulation of nascent polypeptide chains that are potentially toxic for the cell . Within the RQC complex, NEMF specifically binds stalled 60S ribosomal subunits by recognizing an exposed, nascent chain-conjugated tRNA moiety and promotes the recruitment of LTN1 to stalled 60S subunits . Following binding to stalled 60S ribosomal subunits, NEMF mediates CAT tailing by recruiting alanine-charged tRNA to the A-site and directing the elongation of stalled nascent chains independently of mRNA or 40S subunits, leading to non-templated C-terminal alanine extensions (CAT tails) . Mainly recruits alanine-charged tRNAs, but can also other amino acid-charged tRNAs . CAT tailing is required to promote ubiquitination of stalled nascent chains by different E3 ubiquitin-protein ligases . In the canonical RQC pathway (RQC-L), CAT tailing facilitates LTN1-dependent ubiquitination by exposing lysine residues that would otherwise remain buried in the ribosomal exit tunnel (By similarity). In the alternative RQC pathway (RQC-C) CAT tailing creates an C-degron mainly composed of alanine that is recognized by the CRL2(KLHDC10) and RCHY1/PIRH2 E3 ligases, leading to ubiquitination and degradation of stalled nascent chains . NEMF may also indirectly play a role in nuclear export . . |
Accessions | ENST00000298310.10 [O60524-1] L8E842 O60524 ENST00000554626.5 ENST00000556672.1 G3V5V3 ENST00000555970.5 L8E7P7 G3V547 G3V4D9 |